礼来公司的 tirzepatide 在治疗阻塞性睡眠呼吸暂停的 3 期试验中表现出疗效，与安慰剂相比，其可降低 AHI。 Eli Lilly's tirzepatide showed efficacy in phase 3 trials for obstructive sleep apnea, reducing AHI compared to a placebo.

礼来公司的股价上涨了 0.54%，因为其分子 tirzepatide 在治疗阻塞性睡眠呼吸暂停 (OSA) 的 3 期临床试验中成功达到了其主要终点。 Eli Lilly's stock rose 0.54% as its molecule, tirzepatide, successfully met its primary endpoints in phase 3 clinical trials for treating obstructive sleep apnea (OSA). 与安慰剂相比，该药物显著降低了呼吸暂停低通气指数 (AHI)。 The drug significantly reduced the apnea-hypopnea index (AHI) compared to a placebo. 这标志着 OSA 潜在疾病的药物治疗首次取得成功，该疾病影响着美国 8000 万成年人。 This marks a potential first for pharmaceutical treatment of OSA's underlying disease, which affects 80 million adults in the US.